Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KISS1R | Q969F8 | 1/20 | 0.47 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.43 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.41 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.41 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.41 |
| ▸ | NOS2 | P35228 | 5/20 | 0.38 |
| ▸ | NOS1 | P29475 | 4/20 | 0.38 |
| ▸ | NOS3 | P29474 | 3/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | GSR | P00390 | 1/20 | 0.38 |
| ▸ | BLM | P54132 | 1/20 | 0.37 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.36 |
| ▸ | RRM1 | P23921 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | SLC15A1 | P46059 | 1/20 | 0.35 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12825453 | 1.00 | KISS1R (0.47) | KISS1RDPP7GNAI3GNAO1GNAI1 | |
| SCHEMBL1104625 | 1.00 | KISS1R (0.47) | KISS1RDPP7GNAI3GNAO1GNAI1 | |
| SCHEMBL13776588 | 0.94 | KISS1R (0.53) | KISS1RDPP7GNAI3GNAO1GNAI1 | |
| SCHEMBL16602285 | 0.94 | KISS1R (0.53) | KISS1RDPP7GNAI3GNAO1GNAI1 | |
| SCHEMBL15132881 | 0.94 | KISS1R (0.53) | KISS1RDPP7GNAI3GNAO1GNAI1 | |
| SCHEMBL24390551 | 0.89 | DPP7 (0.60) | KISS1RDPP7GNAI3GNAO1GNAI1 | |
| SCHEMBL18752843 | 0.89 | DPP7 (0.60) | KISS1RDPP7GNAI3GNAO1GNAI1 | |
| SCHEMBL10126254 | 0.85 | — | — | |
| SCHEMBL12513982 | 0.85 | — | — | |
| SCHEMBL22381010 | 0.84 | GSR (0.48) | DPP7NOS2NOS1NOS3CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240218164-A1 | POLYMER COMPOSITION AND PREPARATION METHOD THEREFOR | YOUREH CO., LTD. (KR) | 2024-07-04 | — | — | US | disclosed |
| WO-2023152347-A1 | PROCESS FOR MANUFACTURING MACROCYCLIC PEPTIDES | F. HOFFMANN-LA ROCHE AG (CH) | 2023-08-17 | — | — | WO | disclosed |
| US-20230143604-A1 | QW DOSING OF GIP RECEPTOR AGONIST PEPTIDE COMPOUNDS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-05-11 | — | — | US | disclosed |
| WO-2023012263-A1 | SOLID ORAL PEPTIDE FORMULATIONS | NOVO NORDISK A/S (DK) | 2023-02-09 | — | — | WO | disclosed |
| US-20220135638-A1 | GIP RECEPTOR AGONIST PEPTIDE COMPOUNDS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-05-05 | — | — | US | disclosed |
| US-11174301-B2 | Peptide compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-11-16 | — | — | US | disclosed |
| WO-2021193983-A2 | QW DOSING OF GIP RECEPTOR AGONIST PEPTIDE COMPOUNDS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-09-30 | — | — | WO | disclosed |
| WO-2021193984-A2 | QD DOSING OF GIP RECEPTOR AGONIST PEPTIDE COMPOUNDS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-09-30 | — | — | WO | disclosed |
| US-20200140505-A1 | PEPTIDE COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMTED (JP) | 2020-05-07 | — | — | US | disclosed |
| US-10435445-B2 | Peptide compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-10-08 | — | — | US | disclosed |
| US-9890315-B2 | Use of polylysine as a shale inhibitor | BASF SE (DE) | 2018-02-13 | — | — | US | disclosed |
| EP-2737000-B1 | USE OF HYPERBRANCHED POLYLYSINE AS SHALE INHIBITOR | BASF SE (DE) | 2017-06-07 | — | — | EP | disclosed |
| WO-2016046409-A1 | NOVEL PEPTIDE DERIVATIVES AND USES THEREOF | NOSOPHARM (FR) | 2016-03-31 | — | — | WO | disclosed |
| EP-2057188-B1 | DPP-IV RESISTANT GIP HYBRID POLYPEPTIDES WITH SELECTABLE PROPERTIES | AMYLIN PHARMACEUTICALS LLC (US) | 2013-07-31 | — | — | EP | disclosed |
| WO-2013074526-A2 | ANTIMICROBIAL COMPOSITIONS AND METHODS OF USE THEREOF | BYOCOAT ENTERPRISES, INC. (US) | 2013-05-23 | — | — | WO | disclosed |
| US-20130123148-A1 | USE OF POLYLYSINE AS A SHALE INHIBITOR | BASF SE (DE) | 2013-05-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200140505-A1 | PEPTIDE COMPOUND | GIPR, GLP1R, GRPR | KISS1R 111/4885DPP7 79/4885GNAI3 429/4885 |
| US-20230143604-A1 | QW DOSING OF GIP RECEPTOR AGONIST PEPTIDE COMPOUNDS AND USES THEREOF | GIPR, GLP1R, GRPR | KISS1R 87/4885DPP7 90/4885GNAI3 203/4885 |
| US-11174301-B2 | Peptide compound | GIPR, GLP1R, GRPR | KISS1R 111/4885DPP7 79/4885GNAI3 429/4885 |
| US-10435445-B2 | Peptide compound | GIPR, GLP1R, GRPR | KISS1R 103/4885DPP7 71/4885GNAI3 388/4885 |
| US-20220135638-A1 | GIP RECEPTOR AGONIST PEPTIDE COMPOUNDS AND USES THEREOF | GIPR, GLP1R, VIPR1 | KISS1R 50/4885DPP7 115/4885GNAI3 330/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.